Explorez tous les épisodes du podcast Applied Clinical Trials
| Titre | Date | Durée | |
|---|---|---|---|
| ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval | 13 nov. 2026 | 00:01:30 | |
In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor. | |||
| ACT Brief: APAC Sponsor Priorities, Continuous Glucose Monitoring Trials, and GLP-1 Eye Warning | 12 nov. 2026 | 00:01:52 | |
In today’s ACT Brief, we examine three priorities for first-time APAC sponsors, how continuous glucose monitoring should be used in diabetes trials, and why FDA is requiring a new eye-related warning across GLP-1 medications. | |||
| ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval | 11 nov. 2026 | 00:01:41 | |
In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk. | |||
| ACT Brief: China’s Startup Timelines, AI-Drafted Clinical Study Reports, and Bimzelx Psoriatic Arthritis Data | 10 nov. 2026 | 00:01:47 | |
In today’s ACT Brief, we examine how China’s trial startup timelines compare with those in the US and Europe, whether AI-drafted clinical study reports speed drug development, and how Bimzelx compared with Skyrizi in psoriatic arthritis. | |||
| ACT Brief: APAC Inspection Findings, RBQM Key Risk Indicators, and Head and Neck Cancer Approval | 09 nov. 2026 | 00:01:47 | |
In today’s ACT Brief, we examine why APAC inspection findings mirror those in the US and Europe, how key risk indicators should be read together, and how FDA granted accelerated approval to a subcutaneous antibody therapy for recurrent head and neck cancer. | |||
| ACT Brief: Asia Pacific Site Perceptions, Community Access Gap, and VeonGen Gene Therapy Alignment | 06 nov. 2026 | 00:01:39 | |
In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design. | |||
| ACT Brief: Capturing Trial Friction, AI Matching Model Comparisons, and Boehringer’s Oncology Deal | 05 nov. 2026 | 00:01:54 | |
In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group. | |||
| The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time | 04 nov. 2026 | 00:43:12 | |
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss. | |||
| ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal | 04 nov. 2026 | 00:01:57 | |
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis. | |||
| ACT Brief: Embedding AI Across Operations, Faster Trial Decisions, and Voceryq Approval | 03 nov. 2026 | 00:01:36 | |
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease. | |||
| ACT Brief: Community Research Policy Needs, Walmart Trial Centers, and Psoriatic Arthritis Approval | 02 nov. 2026 | 00:01:49 | |
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis. | |||
| ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance | 30 oct. 2026 | 00:01:51 | |
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants. | |||
| ACT Brief: Community Trial Access Technology, RBQM Infrastructure, and Digital Clone Use Cases | 29 oct. 2026 | 00:01:48 | |
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes. | |||
| ACT Brief: Legacy Trial Workflows, Medical Writing Talent Gaps, and Post-Exposure COVID Prevention | 28 oct. 2026 | 00:01:35 | |
In today’s ACT Brief, we examine how legacy workflows pull community clinics away from patient care, why medical writing capacity depends on training rather than technology, and how an antiviral aims to prevent COVID-19 after exposure. | |||
| ACT Brief: Community Trial Cost Barriers, Measuring What Matters, and Prostate Cancer Approval | 27 oct. 2026 | 00:01:52 | |
In today’s ACT Brief, we examine how cost barriers and site infrastructure limit participation in community trials, why endpoints should reflect what patients actually experience, and how the FDA expanded a prostate cancer combination to an earlier treatment setting. | |||
| ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act | 23 oct. 2026 | 00:01:54 | |
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks. | |||
| ACT Brief: Applied Clinical Trials at 2026 SCRS Global Site Solutions Summit | 22 oct. 2026 | 00:01:57 | |
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size. | |||
| ACT Brief: AI Operating Models, Oncology Evidence Trust, and Thyroid Eye Disease Approval | 19 oct. 2026 | 00:01:25 | |
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease. | |||
| ACT Brief: Who Sets Trial Endpoints, Human-Centered Trial Execution, and Bladder Cancer Approval Expansion | 16 oct. 2026 | 00:01:50 | |
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population. | |||
| The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution | 15 oct. 2026 | 00:39:28 | |
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning. | |||
| ACT Brief: EHR-to-EDC Connectivity, FDA’s Rare Disease Framework, and Barriers to Oncology RWE | 15 oct. 2026 | 00:01:55 | |
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers. | |||
| ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License | 14 oct. 2026 | 00:01:59 | |
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer. | |||
| AI and Patient Recruitment: Can Predictive Promise Drive True Transformation? | 09 oct. 2026 | 00:27:06 | |
Can artificial intelligence help turn what many believe is clinical development’s biggest variable — and most prevailing bottleneck — into a more predictable process? In this episode of the Applied Clinical Trials podcast, Matt Walz, CEO of Trialbee, a patient recruitment company, joins Mike Christel, group managing editor, MJH Life Sciences, to discuss how AI is enhancing medical screening, clinical workflows, and enrollment planning. The conversation explores the need for clearer regulatory expectations, human oversight, and workforce training — and why predicting enrollment costs and timelines, Walz believes, could offer one of AI’s most consequential opportunities in clinical trials. Walz also shares how Trialbee is deploying AI on both the patient-facing and operational sides of its business and explains how conversational tools are helping teams move from the world of dashboards to more specific answers. | |||
| ACT Brief: RBQM Analysis Frequency, Building Trust in Oncology Data, and Rare Pediatric PRV Monetization | 09 oct. 2026 | 00:01:50 | |
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success. | |||
| ACT Brief: AI and Protocol Design, Site Training Readiness, and GLP-1 Unmet Needs | 08 oct. 2026 | 00:01:47 | |
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies. | |||
| ACT Brief: FDA Transparency Roadmap, Radiopharmaceutical Trial Operations, and AI-Powered Enrollment Prediction | 07 oct. 2026 | 00:01:56 | |
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable. | |||
| ACT Brief: Ibogaine Trial Design Guidance, Outsourcing Model Oversight Gaps, and Kidney Disease Partnership | 06 oct. 2026 | 00:01:51 | |
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment. | |||
| ACT Brief: AI Adoption Starting Points, Hierarchical Endpoints and Patient Priorities, and Early-Stage Program Termination | 05 oct. 2026 | 00:01:42 | |
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management. | |||
| ACT Brief: Proactive Trial Risk Management, Federal Infrastructure Modernization, Pediatric Heart Disease Treatment | 02 oct. 2026 | 00:01:52 | |
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents. | |||
| ACT Brief: AI as Design Advisor, Autonomous Agent Governance, Oral Weight-Loss Therapy Switch | 01 oct. 2026 | 00:01:54 | |
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy. | |||
| ACT Brief: Enrollment Feasibility Pressure-Testing, RWE Infrastructure Gaps, and Peptide Rulemaking Standstill | 30 sept. 2026 | 00:01:40 | |
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies. | |||
| ACT Brief: Trial Simulations and Protocol Risk, RBQM Financial Value Quantified, and Three Drug Approvals | 29 sept. 2026 | 00:01:51 | |
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease. | |||
| ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval | 28 sept. 2026 | 00:01:52 | |
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer. | |||
| ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy | 25 sept. 2026 | 00:01:55 | |
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy. | |||
| ACT Brief: Data Provenance and Device Strategy, Cell-Gene Therapy Site Readiness, and Data Harmonization Bottleneck | 24 sept. 2026 | 00:02:07 | |
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck. | |||
| Beyond Compliance: Vivalink's Cecilia Xi, PhD, on Data Provenance and Sustainable Device Strategy in Clinical Trials | 23 sept. 2026 | 00:21:27 | |
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends. | |||
| ACT Brief: Patient Journey and Study Design, Decentralization's True Cost, and Europe's Pharma Competitiveness Crisis | 23 sept. 2026 | 00:01:51 | |
In today's ACT Brief, we examine understanding the patient journey from end to end, whether decentralization reduces site burden or just shifts it, and why nine European drugmakers are sounding urgent alarms. | |||
| ACT Brief: Patient-Site Interaction and Technology, AI Pilot Success Requires Discipline, and CagriSema Beats Lilly Drug | 22 sept. 2026 | 00:01:38 | |
In today's ACT Brief, we examine technology's real role in patient-site collaboration, why AI pilot failures stem from organization not innovation, and Novo's weight-loss drug results in competitive comparison. | |||
| ACT Brief: Patient-Site Trust and AI Role, Platform Approach to Scale, Gene Therapy for Pediatric Disease | 21 sept. 2026 | 00:01:39 | |
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome. | |||
| ACT Brief: Patient Voice as Methodology, AI System Bottlenecks, Regulatory Convergence on Patient Input | 18 sept. 2026 | 00:01:47 | |
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements. | |||
| ACT Brief: Expedited IND Pilot Launch, Operating Model Importance, and Readiness Prediction | 17 sept. 2026 | 00:01:45 | |
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk. | |||
| The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data | 16 sept. 2026 | 00:43:33 | |
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins. | |||
| ACT Brief: Epilepsy Trial Feasibility and Family Realities, CRO Partnerships and Strategic Value, and Cortisol and GLP-1 Response | 16 sept. 2026 | 00:01:52 | |
In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes. | |||
| ACT Brief: Endpoint Selection and Patient Engagement, Execution Infrastructure Before AI, and Real-World Data Quality Gaps | 15 sept. 2026 | 00:01:37 | |
In today's ACT Brief, we examine how shifting patient engagement to endpoint selection improves trial data quality, why execution infrastructure must precede AI deployment, and addressing missing baseline data in real-world oncology research. | |||
| ACT Brief: Epilepsy Trial Endpoints, Lab Orchestration and Scientific Intent, and Systems Over Point Solutions | 14 sept. 2026 | 00:01:51 | |
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination requires connecting data to intent, and why healthcare needs orchestration rather than more tools. | |||
| ACT Brief: Patient Voice in Protocol Design, AI-Informed Recruitment Workflows, and Engagement Maturity Beyond Performative | 11 sept. 2026 | 00:01:25 | |
In today's ACT Brief, we examine genuine patient partnership in trial design, how AI enables informed recruitment while preserving clinician relationships, and moving patient engagement beyond performative gestures. | |||
| ACT Brief: Explainable AI for Patient Subgroups, Participant Understanding and Engagement, and FDA Leadership Stabilization | 10 sept. 2026 | 00:01:51 | |
In today's ACT Brief, we examine why black-box AI fails in clinical trials, how participant understanding drives engagement more than gamification, and FDA permanent leadership appointments prioritizing regulatory predictability. | |||
| Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable | 09 sept. 2026 | 00:23:40 | |
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Joseph Geraci, PhD, co-founder and chief scientific and technical officer at NetraMark, about why explainable AI, not black-box prediction, is needed to reveal clinically meaningful patient subgroups in regulated drug development. | |||
| ACT Brief: RBQM Multi-Functional Buy-In and E6(R3), Site Payment Performance and Cash Runway, and Inhaled Therapy for Cystic Fibrosis | 09 sept. 2026 | 00:01:46 | |
In today's ACT Brief, we examine how regulatory guidance and financial evidence enable RBQM adoption, why site payment performance remains a competitive differentiator, and a collaboration advancing an inhaled approach to cystic fibrosis. | |||
| ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD | 08 sept. 2026 | 00:01:39 | |
In today's ACT Brief, we examine value hidden in the RBQM financial model, why rare disease research leads on genuine patient partnership, and how safety concerns shape IBD treatment decisions despite clinical efficacy. | |||